Ultherapy’s real-time visualization and multi-depth targeting ensures precise energy delivery for safe, accurate, and reproducible results, suitable for all skin types.1,2
Extensive Safety Data: Ultherapy’s Evidence Edge Over Sofwave.
Not actual patients.
Ultherapy patients report pain levels of 5.6/10 for forehead, 3.9/10 for temple, and 6.09/10 for submental areas
Ultherapy’s precise energy delivery allows practitioners to target 3 depths of collagen-rich layers without the need for additional
cooling
Ultherapy’s real-time imaging helps practitioners avoid structures like bones and blood vessels while targeting collagen-rich tissue
Sofwave patients report pain levels of 6.4/10 for forehead and 5.3/10 for neck/submental areas
Sofwave necessitates an integrated cooling tip for epidermal protection
Without visualization, practitioners risk complications from improper energy delivery, potentially causing adverse events and increased pain
*For illustrative purposes only, as individual skin layers vary in depth. Do not deliver energy solely to adipose tissue.
Ultherapy offers targeting at depths of 1.5, 3.0, and 4.5 mm, reaching both the deep dermis and collagen-rich fibrous layers
Ultherapy ensures accurate treatment at the same tissue planes as a modern facelift, suitable for all skin types
Ultherapy consistently delivers precise energy without affecting surrounding tissue
Sofwave’s SUPERB™ technology only targets 1.5 mm, unable to reach deeper, collagen-rich fibrous layers
Sofwave’s SUPERB technology may induce thermal injury at depths ranging from 0.5 to 2 mm
Sofwave’s limited depth targeting
and lack of real-time visualization
may result in less precise treatment, potentially affecting
surrounding tissue
Leverage real-time visualization to promote more personalized and effective treatments.
Treatment Example: Cheek Region
Not actual patients.
Practitioners control where energy is deposited with Ultherapy and can adapt to patient anatomy to customize treatment and deliver precise results
Ultherapy enables practitioners to visualize skin layers and deliver energy precisely where needed, tailoring treatment to each patient’s anatomy
Sofwave cannot assess patient anatomical variances
under the skin, limiting the customization of treatments
Without visualization and targeting only 1 treatment depth, providers cannot customize treatment
of market presence3
120+ publications3
performed in 80+ countries worldwide3
Ultherapy boasts robust clinical evidence and a 95% patient satisfaction rate at 1 year
Ultherapy provides a long-lasting lift after a single 30- to 90-minute treatment, lasting up to a year or more
Ultherapy’s efficacy extends far beyond the initial session, with multiple studies demonstrating improvements in skin laxity lasting up to a year or more
Sofwave lacks extensive long-term data and comparable patient satisfaction rates
Sofwave may require multiple treatments for results lasting up to 6 months
As of May 2024, only 1 small study of Sofwave (N=15) demonstrates 6-month improvement, with no additional long-term data
| Feature | Ultherapy | Sofwave |
|---|---|---|
| Multi-depth treatment down to the SMAS1,3,5 | ✔️ | |
| Real-time visualization1,3 | ✔️ | |
| Precision & customization1-3,8 | ✔️ | |
| Results lasting up to a year or more3,10 | ✔️ | |
| Single-session treatment3,10 | ✔️ | |
| No downtime3,14 | ✔️ | ✖️ |
| Effective for all Fitzpatrick skin types4,14 | ✔️ | ✖️ |
Ultherapy PRIME’s ADVANCED platform features a faster and more powerful processing performance, elevated ergonomics, and sophisticated design
Ultherapy PRIME platform is the only FDA-cleared, non-invasive lifting device with VIVID real-time imaging that allows practitioners to assess their patients’ unique needs to promote safer and more effective results.1,2,5,6,8,9,13
Ultherapy PRIME platform builds on the legacy of PROVEN, safe, and effective results, with more than 120 publications, 56 clinical studies, and more than 2.6 million treatments performed in more than 80 countries.3,9,10
The ULTHERA® System is indicated to lift the skin on the neck, on the eyebrow, and under the chin as well as to improve lines and wrinkles on the décolleté. Reported adverse events from post marketing surveillance are available in the Instructions for Use (IFU). Please see the IFU for product and safety information, and possible side effects at Ultherapy.com/IFU.
1. Ultherapy [Instructions for Use]. Mesa, AZ: Ulthera, Inc; 2022.
2. Pavicic T, et al. J Cosmet Dermatol. 2022;21(2):636-647.
3. Data on file. Merz North America, Inc. US-ULT-2300029.
4. Fabi SG. Clin Cosmet Investig Dermatol. 2015;8:47-52.
5. Suh DH, et al. J Cosmet Laser Ther. 2015;17(5):230-236.
6. Whitney ZB, et al. In: StatPearls [Internet]. Updated January 30, 2024. Accessed July 25, 2024. https://www.ncbi.nlm.nih.gov/books/NBK519014/
7. Data on file. Sofwave Inc. PB00041-2.
8. Fabi SG, et al. J Drugs Dermatol. 2019;18(5):426-432.
9. Park JY, et al. J Clin Aesthet Dermatol. 2021;14(5):E70-E79.
10. Werschler WP, Werschler PS. J Clin Aesthet Dermatol. 2016;9(2):27-33.
11. Gold MH, Biron J. J Cosmet Dermatol. 2024;23(1):117-123.
12. Data on file. Merz North America, Inc. GL-ULT-2300002.
13. Fabi SG, et al. J Am Acad Dermatol. 2013;69(6):965-971.
14. Data on file. Sofwave Inc. PB00030-4.
© 2024 Merz North America, Inc. All rights reserved. ULTHERA, ULTHERAPY, ULTHERAPY PRIME, the ULTHERAPY Logo, and the SQUIGGLE Logo are registered trademarks, and THE LIFT YOU CAN SEE is a pending trademark, of Ulthera, Inc. in the U.S. MERZ AESTHETICS is a registered trademark of Merz Pharma GmbH & Co. KGaA in the U.S. All other marks are the property of their respective owners. US-ULT-2400117.